Article Information
History
- April 24, 2020.
Article Versions
- You are currently viewing Version 1 of this article (April 24, 2020 - 03:39).
- Version 2 (April 24, 2020 - 10:12).
- Version 3 (April 30, 2020 - 10:48).
- Version 4 (June 21, 2020 - 17:36).
- Version 5 (June 27, 2020 - 15:00).
- Version 6 (June 28, 2020 - 09:48).
- View Version 7, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Department of Surgery, VA North Texas Health Care System Dallas, TX 75216, USA
- 2Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
- 3Department of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA
- 4Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA 23510, USA
- * Corresponding author; email: awkaljacob{at}gmail.com
↵* These authors contributed equally to this work
Posted April 24, 2020.
Accelerated hyaluronan concentration as the primary driver of morbidity and mortality in high-risk COVID-19 patients: with therapeutic introduction of an oral hyaluronan inhibitor in the prevention of “Induced Hyaluronan Storm” Syndrome
